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T HE effects of dosage form variables on
therapeutic efficacy and/or bioavail-
ability of drugs are well documented.m
Usually, these effects will be manifest
principally in differences in rate of
absorption and/or differences in efficiency
of absorption. Since a formulation which
releases a drug slowly over an extended
time could have the same bioavailability
as a formulation with a more rapid rate
of absorption, it is important to comm-
sider both rate and extent of absorp-
tion as criteria for assessing therapeutic
equivalency.
Uwilt et al.2 mmoted differences imm blood
and plasma levels of aeetaminophen after
administering 1 Gm of drug as whole
tablets (eight different manufacturers), as
crushed tablets (one manufacturer), and
as a tablet containing sorbitol. However,
his comparisons were made at a single
sampling time (45 minutes after adminis-
tration). McGilveray et al.3 compared
efficiencies and rates of absorption of eight
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lots of tablets, one elixir, and an aqueous
solution of acetaminophen in ten subjects
each receiving 1-Gm doses weekly f or ten
weeks. No differences in rate or extent of
availability were noted among formnula-
tions from either blood level or urinary
excretion data after monitoring free drug
as well as total levels.
Mattok et al.4 observed the semmsitivitv
of the bioavailability of mmitrofurantoin to
changes in formulation of the drug. One
liundred-milligrani doses of nitrofurantoin
were administered to 30 subjects in the
form of conmnmercially available tablets
from one manufacturer. Bioavailabilities
based on urinary data were expressed as
per cent of that obtained with a eormtrol
suspension as well as the per cent of the
innovator’s product. An in vivo-in vitro
comparison was attempted, but results in-
dicated that the dissolution tests did not
accurately reflect in vivo absorption.
In a recent study, Horn and MiskeP
demonstrated enhanced in vitro rates of
dissolution for a series of chemically and
pharmacologically different drugs when
formulated in special soft gelatin capsules
compared to commercially available tab-
lets. Since in vitro dissolutiomi rate reflects
the bioavailability potential of a drug in
a dosage form, two human studies were
undertakemi to compare plasma levels and
urinary excretion of the drugs acetamino-
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*The studies were separated by about 6 months; phases were
separated by a 1-week period. For acetaminophen, treatment A is
the soft gelatin capsule (B. P. Scherer Corp.), treatment B is
the commercial tablet (Tylenol, McNeil). For nitrofurantoin,
treatment A is the soft gelatin capsule (B. P. Scherer Corp.),
treatment B is the commercial tablet (Puradantin, Eaton).
phen ammd nitrofurantoin. Single oral
doses given as commercially available
tablets and as specially formulated soft
gelatin capsules were used in these two
studies. (Poloxamer 212 was the sur-
factant in the acetaminophen formulation,
while Poloxamer 212 and Poloxamer 234,
in a ratio of 4 to 1, were used as bases in
the nitrofurantoin capsule.)
Materials and Methods
Ten healthy male volunteers chosen for
each study were selected based upon
criteria previously described.6 The studies
were performed using a Latin-square
crossover design with two groups of five
subjects possessing similar average body
weights. The study conditions were essen-
tially as described previously,6 with the
following modifications.
Acetaminophen. On the mornings ace-
tamninophen was administered, each sub-
ject drank 6 fi oz of water within the first
hour after arisimig and 6 fI oz of water
when the medication was administered.
On each phase of the two-way crossover,
each subject took two 325-mg capsules
(treatment A) or two 325-mg tablets
(treatmemit B), swallowing the prepara-
tions intact. (Treatment A was the soft
gelatin capsule, R. P. Scherer Corp.; treat-
ment B was Tylenol tablets, McNeil Lab-
oratories.) Blood, 10 ml, was withdrawn
from a forearm vein prior to dosing and
at 10, 20, 30, 40, 60, 120, 240, 360, 480,
and 720 minutes after dosing. Zero- to 24-
hour urine specimens were also obtained
and stored in plastic bottles containing 1
ml toluene. After collection, the volume
was measured and the urine was quick-
frozen and kept in a frozen state until
just prior to assay. Plasma and urine
samples were assayed by the GLC pro-
cedure described by Kostenbauder.7
Nit rof urantoin. On the mornings nitro-
furantoin was administered, each subject
drank 6 fi oz of water at -2, -1, 0, + 1,
+ 2, ± 3, + 4, and + 5 hours, where 0 is
the time of dosing. On each phase of the
two-way study, each subject ingested one
capsule (treatment A) or a tablet contain-
ing 100 mg nitrofurantion (treatment B).
(Treatment A was the soft gelatin capsule,
R. P. Scherer Corp.; treatment B here
was Furadantin tablets, Eaton Labora-
tories.) Blood, 10 ml, was withdrawn from
a forearm vein prior to dosing and at 10,
20, 30, 40, 60, 120, and 240 minutes after
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TABLE II
Summary of Average Plasma Concentrations and 24-Hour Urinary Excretion
of Acetaminophen in Ten Normal Subjects Following a Single 650-mg Oral Dose
Significance C. V.
Average plasma concentration level of difference (%) from
(g/ml) between treatment residual
Treatment A Treatment B averages from ANOVA mean square
Time (mm)
10 0.02 2.06 sig. (0.05>P>0.025) 160
20 1.73 4.24 u.s. (O.25>P>0.10) 135
30 2.38 4.91 n.s. (O.10>P>0.05) 83.4
40 3.26 5.69 sig. (0.025>P>0.01) 42.7
60 4.82 6.36 sig. (0.05>P>0.025) 24.6
120 5.36 4.94 u.s. (P>0.25) 23.0
240 3.13 2.54 sig. (0.O1>P>0.005) 13.0
360 1.84 1.50 sig. (0.025>F>.0.01) 13.8
480 1.22 0.83 sig. (0.005>P>0.001) 21.7
720 0.52 0.34 sig. (0.005>P>0.O01) 22.6
Peak (pg/mI) 6.93 7.72 n.s. (P>O.25) 28.6
Time of peak (mm) 84.0 58.0 n.s. (0.1O>P>0.05) 39.3
Area (0-480 mm) 1453 1431 u.s. (P>0.25) 11.1
Area (0-720 mm) 1654 1572 n.s. (P).o.25) 11.1
Amount of unchanged
acctaminophen excreted
in urine in 24 hours
(mg) 12.5 12.4 N.S. (P>0.25) 24.0
* ANOVA=Analysis of variance for crossover design.
TABLE III
Summary of Average Plasma Concentrations of Nitrofurantoin in Ten Normal Subjects
Following a Single 100-mg Oral Dose
Significance
Average plasma concentration level of difference C.V. (%)
(pg/ml) between treatment from residual
Treatment A Treatment B averages from ANOVA mean square
Time (mm)
10 0.231 0.0644 u.s. (O.10>P>0.05) 131.
20 0.364 0.132 sig. (0.025>P).0.O1) 71.1
30 0.645 0.347 n.s. (0.25>P).0.10) 82.5
40 0.836 0.315 sig. (0.05>P>0.025) 82.1
60 0.950 0.355 sig. (0.O1>P>0.005) 59.0
120 1.08 0.799 u.s. (P>0.25) 71.6
240 0.619 0.500 u.s. (P>O.25) 90.0
Peak (pg/nil) 1.47 0.986 sig. (O.025>P>O.001) 31.4
Area (0-240 mm) 197. 126. u.s. (0.10>P>0.o5)* 48.0
* Same results obtained by paired t-test also.
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Fig. 1. Mean acetaminophen plasma levels for ten subjects following a
single 650-my oral (lose: ( S ) treatment A (soft .qelatin cap-
sule); ( __,. ) treatment B (commercial tablet).
dosing. Urine collections were made in the
following time intervals: predosc, 0-2
hours, 2-4 hours, 4-6 hours, 6-8 hours,
8-12 hours, 12-24 hours. The urine sam-
ples were collected in plastic bottles with-
out addition of any preservative. After
collection, the urine volumes were meas-
ured, the urine was quick-frozen, and kept
in the frozen state until just prior to
assay. A modification of the analytical pro-
cedure of Conklin and Holhifields was used
to assay for nitrofurantoin in plasma and
urine samples. (Conklin and Hollifield em-
ployed 1 ml urine, 4 ml 0.131 HO!, and 10
ml nitromethane. In the present study 2
ml urine, two drops concentrated 1101,
and 4 ml nitromethane were used.)
Each blood sample from both studies
was drawn into one Vacutainer tube con-
taining heparin as anticoagulant and the
tubes were treated as described previously.6
The treatment schedules for both studies
are outlined in Table I.
Results
Acetaminophen. Table II summarizes
average plasma concentrations and 24-
hour urinary excretion data for treat-
ments A and B and includes a summary
of results of the analyses of variance.
Figure 1 depicts graphically these average
plasma levels. Inspection of the table indi-
cates that since no significant differences
in total average amounts of unchanged
drug excreted in the urine and in average
areas under the plasma concentration
curves following the two treatments were
obtained, no significant differences in bio-
availability between the two treatments
existed. However, Table II also shows
that average plasma concentrations of
acetaminophen at 10, 40, 60, 240, 360, 480,
and 720 minutes differed significantly.
This suggests that the rates of absorption
were, on the average, significantly differ-
ent following the two dosage forms. Figure
1 reveals that the peak average plasma
40 10 120 160 200 240
TIME. MINUTES
Fig. 2. Mean nitrofurantoin plasma levels for
ten sub jects follouiu.q a single 100-mg oral
dose: ( S ) treatment A (soft gelatin cap-
sule); ( -. ) treatment B (commercial
tablet).
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concentration following treatment A ap-
peared at about 120 minutes, while that
for treatment B appeared at about 60
minutes; this is consistent with the hy-
pothesis that acetaminophen in treatment
B (the commercial tablet) was more
rapidly absorbed than acetaminophen in
treatment A (the soft gelatin capsule).
Nitrofurantoin. Figure 2 depicts the
average plasma levels obtained after oral
administration of nitrofurantoin. Figure 3
summarizes the average urinary excretion
data. A summary from the analyses of
variance appears in tabular form in Tables
111 and IV. Simlce no significant differ-
ences between mean treatment areas and
in amounts of unchanged drug excreted
in the urine were obtained for the two
dosage forms tested, their bioavailabilities
*
a
were considered to be equivalent. How-
ever, the plasma level data suggest that
the drug was absorbed more rapidly fol-
lowing administration of the soft gelatin
capsule than following the commercial
tablet. Table III supports this by showing
that the differences between average
plasma concentrations at 20, 40, and 60
minutes, as well as the difference between
average peak plasma concentrations, were
significant.
Discussion
The total amount of unchanged drug
excreted in the urine and the total area
under the plasma concentration curve are
generally accepted as measures of rela-
tive efficiency of absorption. No significant
differences were shown for either of these
parameters following the two treatments
in both studies. However, for nitrofuran-
tom, the area difference gave a signifi-
cance level between 0.10 and 0.05 (Table
III). This fact coupled with the alternate
significant-not significant pattern dis-
played in Table III suggests that if more
subjects had been used, the plasma level
nonequivalency might have been signifi-
cant at all sampling times to 120 minutes
as well as the area under the curve. This
is supported by the large coefficients of
variation calculated from the residual
mean square at each sampling time, which
are measures of intrasubject variation,
assay error, and unknown sources of vari-
ation.
The time taken for a drug to attain
peak concentration is also a reflection of
the rate of absorption. For acetaminophen,
the difference between the mean times of
individual subjects to attain peak con-
centration was not significant. However,
as seen in Table II, the mean times of 84
and 58 minutes for treatment A and B, re-
spectively, gave a significance level between
0.05 and 0.10; interpolation gave P0.07,
which is a borderline level. Inspection of
Fig. 1, coupled with the observation that
12 16 20 24
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Fig. 3. Mean cumulative amount (nsg) of nitrofurantoin excreted for
ten subjects following a single 100-mg oral dose: ( 5 ) treatment
A (soft gelatin capsule); ( --U-) treatment B (commercial tablet).
statistically significant differences were
obtained between treatment means at all
sampling times after the curves intersect
(about 110 minutes), is strong evidence
that, indeed, the commercial tablet (treat-
ment B) was more rapidly absorbed than
the soft gelatin capsule (treatment A).
For nitrofurantoin, it was difficult to
assign a value for the time of maximum
plasma level owing to the noncontinuous
appearance of the individual subject
plasma curves. Irregular concentration
profiles occurred for subjects 2, 3, 4, 5,
7, 8, and 10.
A discrepancy appears to exist between
the urinary excretion data (Table IV)
Summary of the Average Cumulative Amount of Nitrofurantoin Excreted by Ten
Normal Subjects Following a Single 100-mg Oral Dose of Nitrofurantoin
Cumulative amount excreted
(mg)
Treatment A Treatment B










0-2 23.8 18.3 u.s. (O.25>P>0.10) 41.7
0-4 48.8 47.5 u.s. (P>0.25) 40.9
0-6 57.6 53.2 ns. (P>0.25) 28.2
0-8 58.7 55.3 u.s. (P>o.25) 25.3
0-12 59.1 55.8 u.s. (P>o.25) 25.0
0-24 59.2 56.7 u.s. (P>0.25) 24.9
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and plasma level data (Table III) in the
nitrofurantoin study. The treatment
means of the cumulative amounts of
nitrofurantoin excreted in the urine did
not differ significantly at any time,
whereas somne differences between treat-
nlent average plasma concentrations were
significant up to 60 minutes. This type of
discrepancy between urinary excretion
data and plasma data is difficult to ex-
plain, but an almost identical type of dis-
parity was reported by Langlois et al.9 in
a bioavailability study of a sulfamethazole
combination. A plausible explanation
based upon sampling times seems most
reasonable. All the statistically significant
differences in average plasma level oc-
curred in the first 60 minutes, while the
first urine collection time interval was 0
to 120 minutes. Apparently, urine was not
collected at frequent enough time in-
tervals to demonstrate differences that
were readily delineated by plasma levels.
Summ&ry
In two test panels of ten subjects each,
plasma levels and urinary excretion of
two drugs, acetaminophen and nitro-
furantoin, were measured in order to com-
pare bioavailabilities when the drugs were
formulated as commercial tablets and as
specially formulated gelatin capsules. No
significant differences in relative efficiency
of absorption were obtained between tab-
lets and capsules with either drug. How-
ever, when comparing rates of absorption,
the soft gelatin capsule appeared slightly
superior to the tablet in the nitro-
furantoin study, whereas it appeared
slightly inferior to the tablet in the
acetaminophen study. The differences
were not striking with either drug.
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